{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Neoadjuvant Chemotherapy Switch in Borderline Resectable\/Locally Advanced Pancreatic Cancer","description":"Rick Greene, MD, and Mark Truty, MD, discuss the role of neoadjuvant chemotherapy in the treatment of pancreatic cancer, including the optimal treatment of patients who do not respond to first-line chemotherapy or develop toxicities. Dr. Truty is author of, \u201cNeoadjuvant Chemotherapy Switch in Borderline Resectable\/Locally Advanced Pancreatic Cancer.\u201d Dr. Truty is Associate Professor of Surgery, Mayo Clinic, Rochester, MN, where his clinical practice is in the Division of Subspecialty General Surgery, Department of Surgery. ","author_name":"Speaking of SurgOnc","author_url":"https:\/\/www.surgonc.org\/annals\/speaking-of-surgonc\/","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/23171459\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/23171459"}